Clinical Trial Imaging Market by Offerings (Services, Software, Hardware), Modality (Computed Tomography, Echocardiography, Magnetic Resonance Imaging), End-User, Therapeutic area - Global Forecast 2025-2032
Description
The Clinical Trial Imaging Market was valued at USD 1.50 billion in 2024 and is projected to grow to USD 1.61 billion in 2025, with a CAGR of 8.26%, reaching USD 2.83 billion by 2032.
Overview of how clinical trial imaging has become a strategic, cross-functional capability driving study design, endpoint validation, and operational integration across sponsors and providers
Clinical trial imaging has evolved from a specialized support function into a central strategic capability that shapes study design, safety monitoring, and evidence generation for therapeutic development. Innovations in acquisition hardware, advanced software analytics, and cloud-enabled workflows now converge with regulatory expectations for reproducible imaging endpoints, elevating the role of imaging across phases of clinical development. Sponsors and service providers increasingly view imaging not merely as a data capture mechanism but as a source of objective biomarkers that can de-risk development programs, support label claims, and accelerate regulatory dialogue.
As trial complexity grows, so does the need for integrated imaging operations that span protocol design, centralized reading, quality assurance, and technical support. This shift has intensified collaboration between imaging specialists, biostatisticians, and clinical operations teams, creating demand for multidisciplinary capabilities that can translate raw images into validated, analysis-ready datasets. Furthermore, the maturation of machine learning tools and federated analytics has opened new pathways to extract predictive insights while preserving patient privacy. In short, the introduction sets the stage for how imaging is shaping modern clinical research priorities, operational models, and investment focus across stakeholders.
Analysis of major technological, regulatory, and operational shifts reshaping clinical trial imaging and redefining vendor-sponsor collaboration models
The landscape of clinical trial imaging is experiencing transformative shifts driven by technological advances, regulatory refinement, and changing commercial priorities. High-resolution modalities and combined imaging endpoints are enabling richer phenotyping, while software platforms for standardized image transfer and harmonized reading workflows are reducing variability across sites. These innovations support more precise patient selection and earlier detection of treatment effects, thereby increasing the utility of imaging in adaptive study designs and biomarker-driven trials.
Concurrently, regulatory agencies have clarified expectations for image-based endpoints, encouraging sponsors to embed prespecified analysis plans and robust quality controls early in protocol development. The rise of decentralized trial components and tele-imaging capabilities has expanded the operational footprint, prompting investment in secure cloud infrastructures and vendor interoperability. Market participants also face heightened scrutiny around data provenance and auditability, reinforcing the need for validated software and transparent reading methodologies. Collectively, these shifts are reshaping vendor-sponsor relationships, accelerating platform consolidation, and prioritizing partners that can deliver end-to-end, compliant imaging solutions at scale.
Examination of how the 2025 tariff measures have introduced procurement complexity, altered equipment economics, and accelerated interest in software-first imaging delivery models
The United States tariff landscape in 2025 introduced layers of complexity into global procurement and supply chains that affect clinical trial imaging stakeholders. Import tariffs on select imaging hardware components and ancillary laboratory equipment increased capital expenditure considerations for imaging centers and contract research organizations that maintain on-site diagnostic suites. These cost pressures influenced procurement timelines, prompting some organizations to renegotiate service contracts and explore alternative sourcing strategies to mitigate lead-time disruptions.
In addition, tariff-driven variability in equipment costs catalyzed interest in software-centric models that decouple capital intensity from analytical capability. Trial sponsors and imaging service providers evaluated cloud-native reading platforms, vendor-hosted analysis services, and subscription-based offerings as ways to absorb cost volatility while preserving access to advanced analytics. Regulatory filings and study budgets required closer alignment given the potential for equipment-related delays to impact enrollment and imaging schedules. Overall, tariffs prompted a reassessment of contingency planning, supplier diversification, and the economics of maintaining localized imaging capacity versus leveraging centralized or outsourced models.
In-depth segmentation insights revealing how product-service mixes, imaging modalities, therapeutic focus, and end-user priorities determine operational needs and partnership criteria
Segmentation analysis illuminates how distinct product, modality, therapeutic area, and end-user dimensions shape demand dynamics and service models within clinical trial imaging. Based on Product & Service, the market is studied across Services and Software. The Services category emphasizes operational imaging services, read analysis services, system & technical support services, and trial design & consulting services, revealing that sponsors increasingly seek providers capable of delivering integrated workflows that span from protocol design through blinded central reads. Software offerings, meanwhile, concentrate on image management, analytics, and quality assurance, with a premium placed on validation, regulatory compliance, and interoperability.
Based on Modality, the market is studied across Computed Tomography, Echocardiography, Magnetic Resonance Imaging, Positron Emission Tomography, Ultrasound, and X-Ray, illustrating modality-specific requirements for standardization, acquisition protocols, and reader expertise. Each modality carries unique operational and validation challenges that influence vendor selection and training programs. Based on Therapeutic area, the market is studied across Endocrinology, Immunological Disorder, Infectious Diseases, Neurology, and Oncology, indicating divergent imaging priorities where oncology drives high-resolution volumetric assessments while neurology emphasizes longitudinal quantitative biomarkers. Based on End-User, the market is studied across Academic & Government Research Institutes, Biotechnology Companies, Contract Research Organizations, and Pharmaceutical Companies, highlighting differentiated buying behaviors: academic centers prioritize methodological innovation, biotech firms emphasize speed and flexibility, CROs focus on scalable delivery, and pharmaceutical companies balance global consistency with internal governance. Integrating these segmentation dimensions provides a nuanced view of service design, investment priorities, and partnership models that stakeholders must navigate.
Comprehensive regional perspective showing how infrastructure, regulatory norms, and trial capacity across the Americas, Europe Middle East & Africa, and Asia-Pacific shape imaging deployment
Regional dynamics influence how imaging capabilities are deployed, regulated, and commercialized across trials. In the Americas, advanced infrastructure, strong clinical trial activity, and concentrated commercial investments drive demand for high-throughput reading services and validated analytics, while regulatory guidance emphasizes transparent endpoint definitions and reproducible evidence. Sponsors operating in this region frequently combine onshore and nearshore resources to balance speed with data governance requirements.
In Europe, Middle East & Africa, diverse regulatory environments and a broad spectrum of site capabilities require flexible imaging workflows and localized training programs. Harmonization efforts across European regulatory bodies have incentivized standardized imaging protocols, but variable resource availability in emerging markets within the region continues to present operational heterogeneity. In Asia-Pacific, rapid investment in diagnostic imaging infrastructure, rising clinical research capacity, and government-supported initiatives to expand trial ecosystems have made the region increasingly attractive for multi-regional studies. However, differences in data protection frameworks, site certification levels, and modality availability necessitate careful feasibility assessments and tailored site enablement strategies. Taken together, regional insights underscore the importance of adaptable delivery models, robust quality controls, and culturally informed stakeholder engagement.
Analysis of competitive dynamics and vendor capabilities showing how validation, integration, and partnership strategies define leadership in clinical trial imaging services and software
Company-level dynamics reveal a marketplace where established imaging vendors, specialized software providers, and integrated service organizations compete on depth of expertise, regulatory pedigree, and the ability to scale. Leading service providers differentiate through demonstrated experience in centralized reading, validated analytics, and comprehensive technical support that spans site qualification, acquisition monitoring, and blinded read adjudication. Software providers that prioritize regulatory-ready validation, audit trails, and seamless integration with electronic data capture systems find greater traction among sponsors intent on ensuring endpoint integrity.
Partnership strategies also evolve as companies seek complementary strengths: technology firms align with reading centers to combine algorithmic analytics with clinical interpretation, while CROs expand imaging capabilities via strategic acquisitions or alliances to offer end-to-end trial services. Investment in training, quality assurance programs, and customer success functions becomes a meaningful differentiator as clients demand faster implementation and clearer evidence of compliance. In this competitive environment, firms that balance innovation with rigorous validation and transparent governance will sustain longer-term commercial relationships and command preference during vendor selection processes.
Practical and actionable recommendations for organizational investment, procurement, and cross-functional alignment to strengthen imaging reliability and operational resilience
Industry leaders should adopt pragmatic, high-impact actions to strengthen imaging capabilities, reduce operational friction, and unlock clinical value. First, invest in validated, interoperable software platforms that support secure image transfer, consistent quality control, and audit-ready documentation to meet regulator expectations and enable rapid study start-up. In parallel, prioritize capability development for modality-specific protocols and reader training to ensure reproducibility across geographically dispersed sites. These measures reduce variability and enhance the credibility of imaging endpoints.
Second, pursue diversified delivery models that combine centralized reading and cloud-based analytics with localized technical support, enabling organizations to manage cost volatility and site heterogeneity. Third, formalize supplier diversification and contingency planning for hardware procurement to mitigate tariff and supply-chain risks, while evaluating subscription-based or managed services to lower capital burden. Finally, foster closer integration between imaging experts, biostatisticians, and clinical operations teams to design prespecified imaging analysis plans, incorporate adaptive assessment points, and accelerate regulatory interactions. Collectively, these actions will enhance operational resilience, improve endpoint reliability, and create competitive differentiation.
Transparent multi-source research methodology combining primary interviews, regulatory review, and case study analysis to ensure robust and actionable imaging insights
The research methodology underpinning this analysis combines primary stakeholder engagement, systematic document review, and qualitative synthesis to ensure balanced and verifiable findings. Primary inputs included structured interviews with imaging directors, clinical operations leaders, regulatory affairs specialists, and reading center managers, which provided first-hand perspectives on operational bottlenecks, modality-specific needs, and vendor selection drivers. Secondary sources comprised peer-reviewed literature, regulatory guidance documents, and vendor technical specifications to validate technical assertions and contextualize emerging trends.
Analytical processes emphasized triangulation across data sources and scenario-based sensitivity checks to interpret how technological changes, regulatory clarifications, and supply-chain events coalesce to affect operational decisions. The research also incorporated case study analysis of recent multi-center imaging programs to illustrate practical challenges related to harmonization, training, and quality assurance. Throughout, methodological safeguards focused on transparency of assumptions, traceability of evidence, and clear articulation of limitations so readers can judge applicability to their specific contexts.
Concluding synthesis underscoring how standardized workflows, validated analytics, and cross-functional collaboration will maximize the strategic value of imaging in clinical development
Imaging now occupies a strategic nexus within clinical development, bridging diagnostic precision with rigorous evidence generation. The convergence of advanced modalities, validated software, and cloud-enabled workflows is enabling more informative endpoints, but achieving that potential requires disciplined investments in standardization, regulatory alignment, and vendor governance. Operational resilience, manifested through diversified procurement strategies and adaptable delivery models, will prove essential in the face of supply-chain pressures and evolving tariff regimes.
Moreover, segmentation-aware approaches that align modality selection, therapeutic priorities, and end-user capabilities deliver more predictable outcomes and efficient trial execution. Regional nuances further necessitate tailored feasibility and enablement plans to ensure data integrity across global studies. Ultimately, stakeholders that couple technical innovation with stringent validation and cross-functional collaboration will secure the most value from imaging investments and accelerate the generation of robust clinical evidence.
Note: PDF & Excel + Online Access - 1 Year
Overview of how clinical trial imaging has become a strategic, cross-functional capability driving study design, endpoint validation, and operational integration across sponsors and providers
Clinical trial imaging has evolved from a specialized support function into a central strategic capability that shapes study design, safety monitoring, and evidence generation for therapeutic development. Innovations in acquisition hardware, advanced software analytics, and cloud-enabled workflows now converge with regulatory expectations for reproducible imaging endpoints, elevating the role of imaging across phases of clinical development. Sponsors and service providers increasingly view imaging not merely as a data capture mechanism but as a source of objective biomarkers that can de-risk development programs, support label claims, and accelerate regulatory dialogue.
As trial complexity grows, so does the need for integrated imaging operations that span protocol design, centralized reading, quality assurance, and technical support. This shift has intensified collaboration between imaging specialists, biostatisticians, and clinical operations teams, creating demand for multidisciplinary capabilities that can translate raw images into validated, analysis-ready datasets. Furthermore, the maturation of machine learning tools and federated analytics has opened new pathways to extract predictive insights while preserving patient privacy. In short, the introduction sets the stage for how imaging is shaping modern clinical research priorities, operational models, and investment focus across stakeholders.
Analysis of major technological, regulatory, and operational shifts reshaping clinical trial imaging and redefining vendor-sponsor collaboration models
The landscape of clinical trial imaging is experiencing transformative shifts driven by technological advances, regulatory refinement, and changing commercial priorities. High-resolution modalities and combined imaging endpoints are enabling richer phenotyping, while software platforms for standardized image transfer and harmonized reading workflows are reducing variability across sites. These innovations support more precise patient selection and earlier detection of treatment effects, thereby increasing the utility of imaging in adaptive study designs and biomarker-driven trials.
Concurrently, regulatory agencies have clarified expectations for image-based endpoints, encouraging sponsors to embed prespecified analysis plans and robust quality controls early in protocol development. The rise of decentralized trial components and tele-imaging capabilities has expanded the operational footprint, prompting investment in secure cloud infrastructures and vendor interoperability. Market participants also face heightened scrutiny around data provenance and auditability, reinforcing the need for validated software and transparent reading methodologies. Collectively, these shifts are reshaping vendor-sponsor relationships, accelerating platform consolidation, and prioritizing partners that can deliver end-to-end, compliant imaging solutions at scale.
Examination of how the 2025 tariff measures have introduced procurement complexity, altered equipment economics, and accelerated interest in software-first imaging delivery models
The United States tariff landscape in 2025 introduced layers of complexity into global procurement and supply chains that affect clinical trial imaging stakeholders. Import tariffs on select imaging hardware components and ancillary laboratory equipment increased capital expenditure considerations for imaging centers and contract research organizations that maintain on-site diagnostic suites. These cost pressures influenced procurement timelines, prompting some organizations to renegotiate service contracts and explore alternative sourcing strategies to mitigate lead-time disruptions.
In addition, tariff-driven variability in equipment costs catalyzed interest in software-centric models that decouple capital intensity from analytical capability. Trial sponsors and imaging service providers evaluated cloud-native reading platforms, vendor-hosted analysis services, and subscription-based offerings as ways to absorb cost volatility while preserving access to advanced analytics. Regulatory filings and study budgets required closer alignment given the potential for equipment-related delays to impact enrollment and imaging schedules. Overall, tariffs prompted a reassessment of contingency planning, supplier diversification, and the economics of maintaining localized imaging capacity versus leveraging centralized or outsourced models.
In-depth segmentation insights revealing how product-service mixes, imaging modalities, therapeutic focus, and end-user priorities determine operational needs and partnership criteria
Segmentation analysis illuminates how distinct product, modality, therapeutic area, and end-user dimensions shape demand dynamics and service models within clinical trial imaging. Based on Product & Service, the market is studied across Services and Software. The Services category emphasizes operational imaging services, read analysis services, system & technical support services, and trial design & consulting services, revealing that sponsors increasingly seek providers capable of delivering integrated workflows that span from protocol design through blinded central reads. Software offerings, meanwhile, concentrate on image management, analytics, and quality assurance, with a premium placed on validation, regulatory compliance, and interoperability.
Based on Modality, the market is studied across Computed Tomography, Echocardiography, Magnetic Resonance Imaging, Positron Emission Tomography, Ultrasound, and X-Ray, illustrating modality-specific requirements for standardization, acquisition protocols, and reader expertise. Each modality carries unique operational and validation challenges that influence vendor selection and training programs. Based on Therapeutic area, the market is studied across Endocrinology, Immunological Disorder, Infectious Diseases, Neurology, and Oncology, indicating divergent imaging priorities where oncology drives high-resolution volumetric assessments while neurology emphasizes longitudinal quantitative biomarkers. Based on End-User, the market is studied across Academic & Government Research Institutes, Biotechnology Companies, Contract Research Organizations, and Pharmaceutical Companies, highlighting differentiated buying behaviors: academic centers prioritize methodological innovation, biotech firms emphasize speed and flexibility, CROs focus on scalable delivery, and pharmaceutical companies balance global consistency with internal governance. Integrating these segmentation dimensions provides a nuanced view of service design, investment priorities, and partnership models that stakeholders must navigate.
Comprehensive regional perspective showing how infrastructure, regulatory norms, and trial capacity across the Americas, Europe Middle East & Africa, and Asia-Pacific shape imaging deployment
Regional dynamics influence how imaging capabilities are deployed, regulated, and commercialized across trials. In the Americas, advanced infrastructure, strong clinical trial activity, and concentrated commercial investments drive demand for high-throughput reading services and validated analytics, while regulatory guidance emphasizes transparent endpoint definitions and reproducible evidence. Sponsors operating in this region frequently combine onshore and nearshore resources to balance speed with data governance requirements.
In Europe, Middle East & Africa, diverse regulatory environments and a broad spectrum of site capabilities require flexible imaging workflows and localized training programs. Harmonization efforts across European regulatory bodies have incentivized standardized imaging protocols, but variable resource availability in emerging markets within the region continues to present operational heterogeneity. In Asia-Pacific, rapid investment in diagnostic imaging infrastructure, rising clinical research capacity, and government-supported initiatives to expand trial ecosystems have made the region increasingly attractive for multi-regional studies. However, differences in data protection frameworks, site certification levels, and modality availability necessitate careful feasibility assessments and tailored site enablement strategies. Taken together, regional insights underscore the importance of adaptable delivery models, robust quality controls, and culturally informed stakeholder engagement.
Analysis of competitive dynamics and vendor capabilities showing how validation, integration, and partnership strategies define leadership in clinical trial imaging services and software
Company-level dynamics reveal a marketplace where established imaging vendors, specialized software providers, and integrated service organizations compete on depth of expertise, regulatory pedigree, and the ability to scale. Leading service providers differentiate through demonstrated experience in centralized reading, validated analytics, and comprehensive technical support that spans site qualification, acquisition monitoring, and blinded read adjudication. Software providers that prioritize regulatory-ready validation, audit trails, and seamless integration with electronic data capture systems find greater traction among sponsors intent on ensuring endpoint integrity.
Partnership strategies also evolve as companies seek complementary strengths: technology firms align with reading centers to combine algorithmic analytics with clinical interpretation, while CROs expand imaging capabilities via strategic acquisitions or alliances to offer end-to-end trial services. Investment in training, quality assurance programs, and customer success functions becomes a meaningful differentiator as clients demand faster implementation and clearer evidence of compliance. In this competitive environment, firms that balance innovation with rigorous validation and transparent governance will sustain longer-term commercial relationships and command preference during vendor selection processes.
Practical and actionable recommendations for organizational investment, procurement, and cross-functional alignment to strengthen imaging reliability and operational resilience
Industry leaders should adopt pragmatic, high-impact actions to strengthen imaging capabilities, reduce operational friction, and unlock clinical value. First, invest in validated, interoperable software platforms that support secure image transfer, consistent quality control, and audit-ready documentation to meet regulator expectations and enable rapid study start-up. In parallel, prioritize capability development for modality-specific protocols and reader training to ensure reproducibility across geographically dispersed sites. These measures reduce variability and enhance the credibility of imaging endpoints.
Second, pursue diversified delivery models that combine centralized reading and cloud-based analytics with localized technical support, enabling organizations to manage cost volatility and site heterogeneity. Third, formalize supplier diversification and contingency planning for hardware procurement to mitigate tariff and supply-chain risks, while evaluating subscription-based or managed services to lower capital burden. Finally, foster closer integration between imaging experts, biostatisticians, and clinical operations teams to design prespecified imaging analysis plans, incorporate adaptive assessment points, and accelerate regulatory interactions. Collectively, these actions will enhance operational resilience, improve endpoint reliability, and create competitive differentiation.
Transparent multi-source research methodology combining primary interviews, regulatory review, and case study analysis to ensure robust and actionable imaging insights
The research methodology underpinning this analysis combines primary stakeholder engagement, systematic document review, and qualitative synthesis to ensure balanced and verifiable findings. Primary inputs included structured interviews with imaging directors, clinical operations leaders, regulatory affairs specialists, and reading center managers, which provided first-hand perspectives on operational bottlenecks, modality-specific needs, and vendor selection drivers. Secondary sources comprised peer-reviewed literature, regulatory guidance documents, and vendor technical specifications to validate technical assertions and contextualize emerging trends.
Analytical processes emphasized triangulation across data sources and scenario-based sensitivity checks to interpret how technological changes, regulatory clarifications, and supply-chain events coalesce to affect operational decisions. The research also incorporated case study analysis of recent multi-center imaging programs to illustrate practical challenges related to harmonization, training, and quality assurance. Throughout, methodological safeguards focused on transparency of assumptions, traceability of evidence, and clear articulation of limitations so readers can judge applicability to their specific contexts.
Concluding synthesis underscoring how standardized workflows, validated analytics, and cross-functional collaboration will maximize the strategic value of imaging in clinical development
Imaging now occupies a strategic nexus within clinical development, bridging diagnostic precision with rigorous evidence generation. The convergence of advanced modalities, validated software, and cloud-enabled workflows is enabling more informative endpoints, but achieving that potential requires disciplined investments in standardization, regulatory alignment, and vendor governance. Operational resilience, manifested through diversified procurement strategies and adaptable delivery models, will prove essential in the face of supply-chain pressures and evolving tariff regimes.
Moreover, segmentation-aware approaches that align modality selection, therapeutic priorities, and end-user capabilities deliver more predictable outcomes and efficient trial execution. Regional nuances further necessitate tailored feasibility and enablement plans to ensure data integrity across global studies. Ultimately, stakeholders that couple technical innovation with stringent validation and cross-functional collaboration will secure the most value from imaging investments and accelerate the generation of robust clinical evidence.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
185 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Integration of artificial intelligence algorithms for automated lesion quantification in oncological imaging trials
- 5.2. Adoption of cloud-based imaging data platforms to enable decentralized clinical trial workflows across global sites
- 5.3. Development of quantitative imaging biomarkers for early detection of cardiovascular treatment efficacy in trials
- 5.4. Emergence of hybrid PET/MRI protocols for enhanced multiparametric assessment in neurodegenerative disorder studies
- 5.5. Implementation of real-time mobile imaging devices for remote patient monitoring in decentralized clinical trials
- 5.6. Evolution of regulatory frameworks for standardized imaging endpoint validation in multinational drug development studies
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Clinical Trial Imaging Market, by Offerings
- 8.1. Services
- 8.1.1. Operational Imaging Services
- 8.1.2. Read Analysis Services
- 8.1.3. System & Technical Support Services
- 8.1.4. Trial Design & Consulting Services
- 8.2. Software
- 8.3. Hardware
- 9. Clinical Trial Imaging Market, by Modality
- 9.1. Computed Tomography
- 9.2. Echocardiography
- 9.3. Magnetic Resonance Imaging
- 9.4. Positron Emission Tomography
- 9.5. Ultrasound
- 9.6. X-Ray
- 10. Clinical Trial Imaging Market, by End-User
- 10.1. Academic & Government Research Institutes
- 10.2. Biotechnology Companies
- 10.3. Contract Research Organizations
- 10.4. Pharmaceutical Companies
- 11. Clinical Trial Imaging Market, by Therapeutic area
- 11.1. Endocrinology
- 11.2. Immunological Disorder
- 11.3. Infectious Diseases
- 11.4. Neurology
- 11.5. Oncology
- 12. Clinical Trial Imaging Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Clinical Trial Imaging Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Clinical Trial Imaging Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. Alimentiv Inc.
- 15.3.2. Anagram 4 Clinical Trials
- 15.3.3. Biospective Inc.
- 15.3.4. Boston Imaging Core Lab LLC
- 15.3.5. Cardiovascular Imaging Technologies LLC
- 15.3.6. Clario
- 15.3.7. GE HealthCare Technologies Inc.
- 15.3.8. Icon PLC
- 15.3.9. Image Core Lab Private Limited
- 15.3.10. Imaging Endpoints II LLC
- 15.3.11. Ixico PLC
- 15.3.12. Median Technologies
- 15.3.13. Medical Metrics Inc. by Catalent, Inc.
- 15.3.14. Medidata by Dassault Systèmes
- 15.3.15. Medpace, Inc.
- 15.3.16. Micron Inc.
- 15.3.17. Perceptive Informatics LLC
- 15.3.18. ProScan Imaging LLC
- 15.3.19. Resonance Health Ltd.
- 15.3.20. Voiant Clinical
- 15.3.21. WCG Clinical, Inc.
- 15.3.22. Parexel International Corporation
- 15.3.23. BioTelemetry, Inc.
- 15.3.24. Navitas Life Sciences
- 15.3.25. Invicro, LLC
- 15.3.26. Radiant Sage LLC
- 15.3.27. Image Analysis Ltd
- 15.3.28. Perspectum Ltd
- 15.3.29. Mint Medical GmbH
- 15.3.30. Prism Clinical Imaging, Inc.
- 15.3.31. Quotient Sciences Limited
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
